Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Asset Writedowns and Impairment (2019 - 2026)

Biodesix filings provide 8 years of Asset Writedowns and Impairment readings, the most recent being $5000.0 for Q1 2026.

  • On a quarterly basis, Asset Writedowns and Impairment fell 93.15% to $5000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$19000.0, a 107.82% decrease, with the full-year FY2025 number at $49000.0, down 79.41% from a year prior.
  • Asset Writedowns and Impairment hit $5000.0 in Q1 2026 for Biodesix, up from -$57000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $539000.0 in Q2 2022 to a low of -$419000.0 in Q3 2022.
  • Median Asset Writedowns and Impairment over the past 5 years was $28000.0 (2023), compared with a mean of $36562.5.
  • Biggest five-year swings in Asset Writedowns and Impairment: surged 770.0% in 2024 and later crashed 155.34% in 2025.
  • Biodesix's Asset Writedowns and Impairment stood at $12000.0 in 2022, then soared by 733.33% to $100000.0 in 2023, then grew by 3.0% to $103000.0 in 2024, then tumbled by 155.34% to -$57000.0 in 2025, then soared by 108.77% to $5000.0 in 2026.
  • The last three reported values for Asset Writedowns and Impairment were $5000.0 (Q1 2026), -$57000.0 (Q4 2025), and $7000.0 (Q3 2025) per Business Quant data.